Health 2.0 Europe 2016

11 - 12 May 2016, Barcelona, Spain.
The 7th edition of Health 2.0 Europe is coming back to Barcelona for 3 full days of content that will explore European and international innovation in patient-provider communication, consumer health, data analytics and more.

Over 120 speakers and 600 attendees from around the world will reconvene to experience over 50 live product demos of innovative solutions that will shake up European health systems.

Confirmed keynotes already include:

  • Esther Dyson, Chairman, EDventure Holdings (USA)
  • Dr. Rafael Grossmann, Practicing surgeon and digital health pionneer (USA)
  • Damien Marmion, Global Head of Health, AXA (France)
  • Dr. Julio Mayol, Director of Innovation, Hospital Clinico San Carlos (Spain)
  • Pēteris Zilgalvis, Head of Unit, eHealth and Well Being – DG CONNECT, European Commission (Belgium)

Confirmed digital health champions also include:

  • Artem Andrianov, CEO, Cyntegrity (Germany)
  • Jani Ahonala, Co-founder & Chairman of the Board, Noona Healthcare, (Finland)
  • Dr. Tom Albert, Director - Health Strategy, AXA Krankenversicherung AG (Germany)
  • Jordina Arcal, Co-founder & COO, HealthApp (Spain)
  • Dr. Alexander Börve, Founder and CEO, FirstDerm.com (Sweden/USA)
  • Vas Bailey, Principal, Quid, Inc (USA)
  • Vedran Boškić, Healthcare ICT consultant, Parsek (Slovenia)
  • Joan Cornet, mHealth Director, Mobile World Capital (Spain)
  • Dustin DiTommaso, SVP, Behavior Change Design, Mad*Pow (USA)
  • Dr. Eduardo García Cruz, Urologist and Men’s Health Specialist, Barcelona Hospital Clinic (Spain)
  • Jorge Gonzalez, Managing Director, TICBioMed (Spain)
  • Jamison Feramisco, President and Co-Founder, Transfuse Solutions, Inc. (USA)
  • Tal Givoly, CEO and Co-founder, Medivizor (Israel)
  • Jorge Gonzalez Olalla, Managing Director, TICBioMed (Spain)
  • Min-Sung Sean Kim, Partner, XL Health (Germany)
  • Jörg Land, CEO, Tinnitracks (Germany)
  • Robert Milnes, CEO, Fertility Focus Limited (United Kingdom)
  • Peter Ohnemus, President & CEO, Dacadoo (Switzerland)
  • Pablo Pantaleoni, CEO, MedTep (Spain/USA)
  • Michael Seres, Founder, 11Health (United Kingdom)
  • Dr. Alexander Schachinger, CEO, EPatient RSD (Germany)
  • Mitchell Silva, Founder and CEO, Esperity (Belgium)
  • Marta Sjögren, Principal, Northzone (Sweden)
  • Pierre Socha, Investment Manager, Amadeus Capital Partners (United Kingdom)
  • Ed Stafford, Director of Informatics, Genomics England (United Kingdom)
  • Unity Stoakes, ‎Co-founder and President, StartUp Health (USA)
  • Donato Tramuto, President and CEO, Healthways and Founder, Health eVillages, (USA)
  • Salvador Vera, CEO, MYSPHERA (Spain)
  • Frank Westermann, Co-founder and CEO, mysugr (Austria)

A mix of visionary keynotes and interactive panel discussions, the 2016 edition will cover some of the following overarching themes:

  • Building blocks to a dynamic health innovation ecosystem
  • Data analytics: Structuring information for decision making
  • Solutions for hospitals and health professionals
  • Gamification and design strategies for behaviour change
  • Pharma 2.0: Going beyond the pill
  • Who will pay for Health 2.0?
  • Reimbursement - Players, trends, criteria and processes
  • The rise of consumer health interfaces
  • "SHUSH topics" and the infamous Unmentionables
  • Health 2.0 applications in emerging markets

For further information and to register, please visit:
https://goo.gl/IVCb3P

PS: Get 15% discount to attend Health 2.0 Europe 2016 using the code EHNEWS16

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...